CD274 and non-small cell lung carcinoma: Several trials have demonstrated the efficacy of pembrolizumab, an immune checkpoint inhibitor, in patients with advanced non-small cell lung cancer (NSCLC) exhibiting a high expression level of programmed death-ligand 1 (PD-L1) (tumor proportion score [TPS] ≥ 50%) [1–4].